{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:11:31Z","timestamp":1760015491620},"reference-count":74,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1053\/j.seminoncol.2015.09.030","type":"journal-article","created":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T19:13:23Z","timestamp":1443122003000},"page":"876-886","source":"Crossref","is-referenced-by-count":15,"title":["Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia"],"prefix":"10.1053","volume":"42","author":[{"given":"Musa","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2015.09.030_bib1","first-page":"751","article-title":"The molecular biology of chronic myeloid leukaemia","volume":"10","author":"Melo","year":"1996","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib2","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib3","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Raitano","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib4","series-title":"Cancer Facts & Figures 2015","year":"2015"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib5","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib6","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib8","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2005.03.2011","article-title":"Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment","volume":"24","author":"Iacobucci","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib11","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib12","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib13","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib14","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib15","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib16","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib17","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib18","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib19","doi-asserted-by":"crossref","unstructured":"Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA180-056). ASH 2014. Abstract 152.","DOI":"10.1182\/blood.V124.21.152.152"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib20","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib22","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","article-title":"Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib","volume":"18","author":"Manley","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u02bcBrien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib24","article-title":"International Randomized Study of Interferon V STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","author":"Deininger","year":"2009","journal-title":"ASH"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib25","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib26","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s12185-014-1566-2","article-title":"Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study","volume":"99","author":"Baccarani","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib28","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib29","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cncr.25438","volume":"117","author":"Cortes","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib30","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2009.016766","article-title":"Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia","volume":"95","author":"Deenik","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib31","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2003-04-1010","article-title":"Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase","volume":"102","author":"Gardembas","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib32","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2005.01.020","article-title":"AMN107: tightening the grip of imatinib","volume":"7","author":"O\u02bcHare","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib34","article-title":"Efficacy and safety of nilotinib (NIL) v imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd","year":"2014","journal-title":"ASH"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib35","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib37","article-title":"Spirit 2: An NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML","year":"2014","journal-title":"ASH"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib38","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib39","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib40","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib41","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u02bcHare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib43","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib44","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib45","article-title":"Epic: A phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML)","author":"Lipton","year":"2014","journal-title":"ASH"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/OPTH.S8521","article-title":"Periorbital edema secondary to imatinib mesylate","volume":"4","author":"McClelland","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib47","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/10428190801959034","article-title":"Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis","volume":"49","author":"Kyathari","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10428190600923157","article-title":"Unusual fluid retention with imatinib therapy for chronic myeloid leukemia","volume":"48","author":"Ostro","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib49","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib52","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Cancer drugs in the United States: Justum Pretium--the just price","volume":"31","author":"Kantarjian","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib53","series-title":"Magic cancer bullet: how a tiny orange pill is rewriting medical history","author":"Vasella","year":"2003"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib54","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib55","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.amjmed.2009.04.012","article-title":"Medical bankruptcy in the United States, 2007: results of a national study","volume":"122","author":"Himmelstein","year":"2009","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.clml.2013.05.011","article-title":"Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials","volume":"13","author":"Yilmaz","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib57","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-015-0254-5","article-title":"Selecting the best frontline treatment in chronic myeloid leukemia","volume":"10","author":"Yilmaz","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib58","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JCO.2011.39.6655","article-title":"Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib60","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib61","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib62","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib63","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib64","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib65","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib66","article-title":"Any BCR-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months","author":"Branford","year":"2013","journal-title":"ASH"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib67","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib68","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/cncr.24325","article-title":"Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib69","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib70","doi-asserted-by":"crossref","unstructured":"Sasaki K, Strom SS, O\u02bcBrien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186-e193.","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib71","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib72","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib73","article-title":"Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: the EURO-SKI study","year":"2014","journal-title":"ASH"},{"key":"10.1053\/j.seminoncol.2015.09.030_bib74","author":"Rea","year":"2014","journal-title":"ASH"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415002006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415002006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T18:28:43Z","timestamp":1599589723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775415002006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0093775415002006"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.030","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}